The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value

Pascale A. Cohen; Caterina F. Donini; Nhan T. Nguyen; Hubert Lincet; Julie A. Vendrell

doi:10.18632/oncotarget.5893

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value

Pascale A. Cohen _, Caterina F. Donini, Nhan T. Nguyen, Hubert Lincet and Julie A. Vendrell

PDF | HTML | How to cite

Oncotarget. 2015; 6:41566-41581. https://doi.org/10.18632/oncotarget.5893

Metrics: PDF 2555 views | HTML 3641 views | ?

Abstract

Pascale A. Cohen1,2,3, Caterina F. Donini1,2,3, Nhan T. Nguyen1,2,3, Hubert Lincet1,2,3 and Julie A. Vendrell1,2,3

1 ISPB, Faculté de Pharmacie, Lyon, France

2 Université Lyon 1, Lyon, France

3 INSERM U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France

Correspondence to:

Pascale A. Cohen, email:

Keywords: ZNF217, oncogene, biomarker, hallmarks of cancer, carcinogenesis

Received: August 03, 2015 Accepted: September 18, 2015 Published: September 29, 2015

Abstract

The recently described oncogene ZNF217 belongs to a chromosomal region that is frequently amplified in human cancers. Recent findings have revealed that alternative mechanisms such as epigenetic regulation also govern the expression of the encoded ZNF217 protein. Newly discovered molecular functions of ZNF217 indicate that it orchestrates complex intracellular circuits as a new key regulator of tumorigenesis. In this review, we focus on recent research on ZNF217-driven molecular functions in human cancers, revisiting major hallmarks of cancer and highlighting the downstream molecular targets and signaling pathways of ZNF217. We also discuss the exciting translational medicine investigating ZNF217 expression levels as a new powerful biomarker, and ZNF217 as a candidate target for future anti-cancer therapies.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5893

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value

Abstract